Background {#Sec1}
==========

Asthma is common in children and is a leading cause of childhood hospitalisation \[[@CR1]\]. National and international guidelines advocate the use of inhaled long-acting beta-2 agonists (LABA) in combination with inhaled corticosteroids (ICS) as maintenance therapy for children ages 5--11 years who remain symptomatic despite medium doses of ICS \[[@CR2], [@CR3]\]. A network meta-analysis including over 12,000 patients across 35 studies found that combined ICS/LABA treatments were more effective than low-dose ICS in preventing asthma exacerbations among paediatric patients \[[@CR4]\]. In addition, studies indicate that the addition of LABA to a low dose of ICS can provide benefits such as improved asthma control in some children compared with increasing the ICS dose \[[@CR5]\] and a reduced impact on growth by 1.2 cm/year compared with double the dose of ICS \[[@CR6]\].

Despite the availability of effective therapies, many children with asthma remain uncontrolled, with low adherence proposed as a potential contributing factor \[[@CR7], [@CR8]\]. In addition, studies in adult and adolescent patients using dry powder inhalers for treatment of asthma and chronic obstructive pulmonary disease have shown that adherence with a once-daily regimen is greater than with a twice-daily regimen \[[@CR9], [@CR10]\]. However, currently available ICS/LABA combination therapies require a twice-daily regimen \[[@CR11], [@CR12]\].

Vilanterol (VI) is a potent, inhaled LABA which, in combination with the ICS fluticasone furoate (FF), has been approved for the treatment of asthma in adults and adolescents in the EU, and in adults in the US \[[@CR13]--[@CR15]\]. In preclinical in vitro studies, VI demonstrated a selectivity profile for beta-2 adrenoceptors (over beta-1 and beta-3 adrenoceptors) that was similar to salmeterol and greater than formoterol and indacaterol \[[@CR16]\]. Persistence and reassertion studies also showed a persistence of action comparable with indacaterol and greater than formoterol \[[@CR16]\]. VI is currently being explored as the LABA component of FF/VI for once-daily treatment for asthma in children \[[@CR17]\]. The objective of this study was to evaluate the dose--response, efficacy, and safety of three doses of VI (6.25 μg, 12.5 μg and 25 μg) administered once daily in the evening over a 4-week treatment period whilst on background fluticasone propionate (FP) therapy to children with asthma who were inadequately controlled on ICS.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a Phase IIb, multicentre, randomised, double-blind, parallel-group, placebo-controlled (with rescue medication) study in children ages 5--11 years with persistent asthma who were still symptomatic on low-dose ICS (ClinicalTrials.gov identifier NCT01573767). The study design consisted of a 4-week run-in period, a 4-week treatment period and a 1-week follow-up (contact) period. At the start of the run-in period, children replaced their current asthma medication with open-label FP 100 μg twice daily via DISKUS®/ACCUHALER® (GlaxoSmithKline), which they continued to take for the duration of the study. A total of 73 centres in 14 countries (Argentina, Chile, Georgia, Germany, Japan, Mexico, Peru, Philippines, Poland, Puerto Rico, Slovakia, South Africa, United States of America and Ukraine) randomised subjects.

Participants {#Sec4}
------------

Children eligible for inclusion were males and pre-menarchial females with inadequately controlled asthma, ages 5--11 years, with at least a 6-month history of asthma and who had been receiving a stable dose of a ICS (total daily dose of FP 200--250 μg or equivalent) and rescue short-acting inhaled beta-agonist (SABA) for at least 4 weeks prior to screening. Eligible children had a pre-bronchodilator peak expiratory flow (PEF) of 50−90 % of their best post-bronchodilator value. Excluded children had: a history of life-threatening asthma; a change in asthma medication within 4 weeks of screening; an asthma exacerbation (defined as either requiring the use of systemic corticosteroids for ≥3 days, a depot corticosteroid injection within 3 months prior to screening, or hospitalisation for asthma within 6 months prior to screening); or a concurrent respiratory disease or any other clinically significant medical condition.

At the end of the run-in period, children eligible for randomisation had a pre-bronchodilator PEF of 50−90 % of their best post-bronchodilator value, had demonstrated symptoms of asthma and/or daily use of albuterol/salbutamol on ≥3 of the last 7 consecutive days of the run-in period, complied with the run-in medication on ≥4 of the last 7 consecutive days of the run-in period and had completed all questions on the Daily Diary on ≥4 out of the 7 days during the screening period. Children could not have experienced an asthma exacerbation between screening and randomisation.

The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and was approved by the relevant ethics committee or institutional review board at each investigational centre. Written informed consent was obtained from two parents/legal guardians. If applicable, the child had to be able and willing to give assent to take part in the study according to the local requirements. The investigator was accountable for determining a child's capacity to assent.

Treatment and assessments {#Sec5}
-------------------------

Children were randomly assigned (1:1:1:1) to receive either placebo, VI 6.25 μg, VI 12.5 μg, or VI 25 μg once daily as their double-blind evening treatment (between 3 pm and 9 pm) in addition to continuing open-label FP 100 μg twice daily. Randomisation was performed via an interactive voice response system whereby children were assigned a randomisation number from a randomisation schedule created by GSK. Children were issued with a daily eDiary and a peak flow meter, and recorded morning and evening PEF, daytime and night time asthma symptom scores, day and night inhalations of SABA and the use of open-label ICS medication during the run-in period. Pre-dose forced expiratory volume in one second (FEV~1~) was measured electronically by spirometer at evening study visits at screening, randomisation, Week 2 and Week 4. These measurements were taken within ±1 h of the time FEV~1~ was measured at baseline and approximately 24 h after the child's last evening dose. Children who were unable to perform acceptable quality FEV~1~ at randomisation did not have to perform the spirometry assessments at subsequent study visits, however, data from these children were still collected for all other endpoints.

The primary endpoint was the mean change from baseline in daily pre-dose trough evening PEF, recorded using an eDiary, averaged over the 4-week treatment period. Secondary endpoints were: 1) change from baseline in evening study visit trough FEV~1~ at the end of the 4-week treatment period (using last observation carried forward \[LOCF\] for imputation of missing post-baseline FEV~1~ values); 2) change from baseline in percentage of rescue-free and symptom-free 24-h periods averaged over the 4-week treatment period; 3) change from baseline in morning PEF averaged over the 4-week treatment period; and 4) mean change from baseline in morning and evening PEF over the last 7 days of the treatment period. Other endpoints were change from baseline in childhood asthma control test (cACT) score at the end of the 4-week treatment period and the percentage of subjects controlled, defined as a cACT score ≥20. A post-hoc analysis was carried out to determine the change from baseline in cACT score according to whether children had a baseline cACT score of \<20 or ≥20.

Pharmacokinetic (PK) blood samples were collected pre-dose and 10−15 min post-dose during the Week 4 visit. Plasma samples were analysed for VI using techniques based on solid phase extraction followed by high-performance liquid chromatography and tandem mass spectrometry analysis (the lower limit of quantification \[LLQ\] was 10 pg/mL, using a 200 μL aliquot).

Safety was assessed by incidence of adverse events (AEs) and exacerbations throughout the 4-week treatment period; vital signs (pulse rate, systolic and diastolic blood pressure \[BP\]) at randomisation and at Week 2, Week 4 or early withdrawal; pre-dose and post-dose electrocardiogram (ECG) at randomisation and at Week 4 or early withdrawal; and laboratory assessments (haematology, clinical chemistry and liver function tests) at screening, Week 4 or early withdrawal.

Statistical analysis {#Sec6}
--------------------

With 460 children (115 per treatment group) the study had 90 % power assuming a difference of 12 L/min between VI and placebo in evening PEF, a standard deviation of 28 L/min and significance declared at the two-sided 5 % level. In order to account for multiplicity across treatment comparisons for the primary efficacy endpoint, a step-down closed testing procedure was applied whereby inference for VI 12.5 μg versus placebo was dependent upon statistical significance having first been achieved for VI 25 μg versus placebo. Similarly, inference for VI 6.25 μg versus placebo was dependent upon statistical significance having first been achieved for VI 12.5 μg versus placebo.

The intention-to-treat (ITT) population comprised all children randomised to treatment who received ≥1 study medication; the per-protocol (PP) population comprised all children in the ITT population who did not have any full protocol deviations; and the PK population consisted of children in the ITT population for whom a PK sample was obtained and analysed for VI.

The analysis of the primary efficacy endpoint was performed using an analysis of covariance (ANCOVA) model allowing for the effects due to baseline evening PEF, region, sex, age and treatment group on the ITT and PP populations. Missing data were not imputed in this analysis. Five sensitivity analyses were performed to examine the impact of missing data on the primary endpoint: one mixed modelling repeated measures (MMRM) model analysis, and four multiple imputation sensitivity analyses. The MMRM analysis allowed for effects due to baseline evening PEF, region, sex, age, week and treatment group, including week-by-treatment and week-by-baseline interaction terms. The four imputation sensitivity analyses analysed the mean change from baseline in evening PEF using a Missing at Random approach, a Copy Increment from Reference approach, a Jump to Reference approach and a Copy Reference approach. An average treatment effect across Weeks 1−4 was obtained for all sensitivity analyses of the primary endpoint. Three further supporting analyses were also performed on the primary endpoint; these were dose response models, Bayesian analyses with non-informative priors and a MMRM model presenting estimates from each week.

Statistical analyses for secondary endpoints were performed using ANCOVA models with effects due to baseline, region, sex, age and treatment group. For trough FEV~1~ and morning/evening PEF at the endpoint, missing data was imputed using LOCF. Programming was performed using SAS Version 9.1.3 or later.

Percent predicted FEV~1~ values at screening and baseline were not pre-specified and are reported as posthoc analyses.

Results {#Sec7}
=======

Demographics {#Sec8}
------------

A total of 1208 children were screened; 463 children were randomised with 456 (98 %) children included in the ITT population (Fig. [1](#Fig1){ref-type="fig"}). Overall, 81 (18 %) children withdrew prematurely from this 4-week study, the majority (62 children, 14 %) withdrawing due to lack of efficacy. The study period, from the first screening to the last visit, was from April 2012 to April 2014. Demographics were comparable between the four treatment groups and are summarised in Table [1](#Tab1){ref-type="table"}. Lung function measures at screening and baseline are shown in Table [2](#Tab2){ref-type="table"}. PEF and FEV~1~ values were similar across treatment groups and stable during the run-in period with open-label FP.Fig. 1Participant flow diagram. Abbreviations: *VI*, vilanterolTable 1Summary of demographic characteristics and baseline characteristics (ITT population)DemographicPlaceboVI 6.25 μgVI 12.5 μgVI 25 μgTotal*N* = 115*N* = 114*N* = 113*N* = 114*N* = 456Sex, *n* (%)Female50 (43)43 (38)42 (37)45 (39)180 (39)Male65 (57)71 (62)71 (63)69 (61)276 (61)Age, yearsMean (SD)8.0 (1.81)8.0 (1.95)7.9 (1.74)7.9 (1.72)7.9 (1.80)Age group, *n* (%)5--7 years51 (44)48 (42)42 (37)46 (40)187 (41)8--11 years64 (56)66 (58)71 (63)68 (60)269 (59)Race, *n* (%)White68 (59)63 (55)55 (49)62 (54)248 (54)White and American Indian or Alaska Native20 (17)19 (17)26 (23)24 (21)89 (20)American Indian or Alaska Native16 (14)21 (18)17 (15)18 (16)72 (16)Asian6 (5)6 (5)7 (6)6 (5)25 (5)African American/African heritage5 (4)5 (4)5 (4)3 (3)18 (4)White and African American/African heritage002 (2)02 (\<1)African American/African heritage and American Indian or Alaska Native001 (\<1)01 (\<1)African American/African heritage and Asian0001 (\<1)1 (\<1)Ethnicity, *n* (%)Hispanic/Latino81 (70)82 (72)82 (73)82 (72)327 (72)Not Hispanic/Latino34 (30)32 (28)31 (27)32 (28)129 (28)Baseline patient-reported outcomesRescue-free 24-h periods (SD), %18.8 (34.20)20.3 (35.65)19.1 (33.73)17.9 (33.60)-Symptom-free 24-h periods (SD), %10.5 (22.50)7.9 (19.98)10.2 (22.35)6.7 (19.30)-cACT score ≥20, *n* (%)58 (50)49 (43)48 (42)46 (40)-*cACT* childhood asthma control test, *ITT* intention-to-treat, *SD* standard deviation, *VI* vilanterolTable 2Lung function measures at screening and baseline (ITT population)Lung function measuresPlaceboVI 6.25 μgVI 12.5 μgVI 25 μgTotal*N* = 115*N* = 114*N* = 113*N* = 114*N* = 456ScreeningPre-bronchodilator PEF (L/min)*n*115114113114456Mean185.05178.35179.22177.09179.94SD59.3055.6760.5755.6857.74Post-bronchodilator PEF (L/min)*n*115114113114456Mean238.79232.29234.54228.37233.51SD67.4169.8069.7972.2969.71Percentage of pre- to post-bronchodilator PEF (%)*n*115114113114456Mean76.9576.8675.8778.0276.93SD9.189.5710.908.179.50Pre-bronchodilator FEV~1~ (L)*n*919197102381Mean1.4051.3701.3741.3611.377SD0.4080.4230.4450.4290.426Post-bronchodilator FEV~1~ (L)*n*999896103396Mean1.7001.7021.6991.6801.695SD0.4570.5320.4650.4960.487Pre-bronchodilator FEV~1~ (% predicted)^a^*n*919197102381Mean86.8382.9285.0484.0884.70SD19.8317.0017.3416.7717.73Post-bronchodilator FEV~1~ (% predicted)^a^*n*999896103396Mean106.81101.10104.34104.58104.22SD20.9418.4716.6819.9719.15BaselinePre-bronchodilator PEF (L/min)*n*115114113114456Mean186.27185.08181.24179.39183.00SD60.6459.1755.1956.8257.88Percentage of pre- to post-bronchodilator PEF (%)*n*115114113114456Mean77.7779.5477.5879.1378.51SD10.499.0910.119.779.88Pre-bronchodilator FEV~1~ (L)^b^*n*969197103387Mean1.3671.4081.3611.3651.374SD0.4210.4540.3980.3980.416Pre-bronchodilator FEV~1~ (% predicted)^a,b^*n*969197103387Mean84.3783.9985.4385.7584.91SD19.3516.9917.6618.3818.08*FEV* ~*1*~ forced expiratory volume in one second, *ITT* intention-to-treat, *PEF* peak expiratory flow, *SD* standard deviation, *VI* vilanterol^a^% predicted FEV~1~ data are posthoc analyses^b^Three children had post-dose FEV~1~ at baseline and were not included in any FEV~1~ secondary endpoint analyses

Primary endpoint {#Sec9}
----------------

The adjusted treatment differences in the mean change from baseline in daily pre-dose trough evening PEF versus placebo were 5.5 L/min, 6.4 L/min and 4.4 L/min, for the VI 6.25, VI 12.5 and VI 25 groups, respectively (Fig. [2](#Fig2){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). The adjusted treatment difference between the VI 25 and placebo groups was not statistically significant (*p* = 0.227). Therefore, in accordance with the step-down closed testing procedure, no statistical inference was made for the comparisons of VI 12.5 μg or VI 6.25 μg with placebo. The analysis of the primary endpoint using the PP population plus all sensitivity and supporting analyses using the ITT population supported the findings of the primary analysis. There was no apparent VI dose-ordering in the evening PEF treatment difference values from placebo.Fig. 2LS mean change from baseline in evening PEF averaged over Weeks 1 to 4 (ITT population). Abbreviations: *ITT*, intention-to-treat; *LS*, least squares; *PEF*, peak expiratory flow; *SE*, standard error, *VI*, vilanterolTable 3Secondary outcomes (ITT population)PlaceboVI 6.25 μgVI 12.5 μgVI 25 μg*N* = 115*N* = 114*N* = 113*N* = 114Primary endpointMean change from baseline in daily evening PEF Weeks 1--4 (L/min)*n*113113112110LS mean215.9221.4222.4220.3LS mean change (SE)4.5 (2.53)10.0 (2.53)11.0 (2.54)8.9 (2.56)Diff. vs placebo5.56.44.495 % CI−1.6, 12.5−0.6, 13.5−2.7, 11.4*p*-value0.1270.0730.227Secondary endpointsChange from baseline in trough FEV~1~ (L) at Week 4 (LOCF)*n*85838686LS mean1.6161.5591.6321.586LS mean change (SE)0.223 (0.029)0.166 (0.029)0.240 (0.029)0.193 (0.029)Diff. vs placebo−0.0570.017−0.03095 % CI−0.138, 0.024−0.063, 0.096−0.110, 0.051Change from baseline in percentage of rescue-free 24-h periods, Weeks 1--4*n*113113112110LS mean change (SE)14.4 (2.97)12.2 (2.97)15.8 (2.98)23.1 (3.01)Diff. vs placebo−2.31.38.795 % CI−10.5, 6.0−6.9, 9.60.4, 17.0Change from baseline in percentage of symptom-free 24-h periods, Weeks 1--4*n*113113112110LS mean change (SE)9.9 (2.65)10.1 (2.65)18.3 (2.66)19.7 (2.69)Diff. vs placebo0.28.39.895 % CI−7.2, 7.51.0, 15.72.3, 17.2Change from baseline in morning PEF (L/min), Weeks 1--4*n*114113112110LS mean206.3211.8213.8213.5LS mean change (SE)6.4 (2.42)12.0 (2.43)13.9 (2.44)13.7 (2.46)Diff. vs placebo5.57.57.295 % CI−1.2, 12.30.7, 14.20.4, 14.0Change from Baseline in morning PEF (L/min), endpoint -- Week 4 (LOCF)*n*114113112110LS mean207.2213.1216.9214.2LS mean change (SE)7.4 (3.45)13.3 (3.47)17.0 (3.48)14.4 (3.51)Diff. vs placebo5.99.77.095 % CI−3.7, 15.60.0, 19.3−2.7, 16.7Change from Baseline in evening PEF (L/min), endpoint - Week 4 (LOCF)*n*113113112110LS mean217.3220.8225.1222.5LS mean change (SE)5.9 (3.44)9.4 (3.44)13.7 (3.45)11.1 (3.48)Diff. vs placebo3.57.85.295 % CI−6.1, 13.1−1.8, 17.4−4.4, 14.9Other endpointsChange from baseline in cACT score by baseline category at Week 4^a^Baseline cACT Score \<20*n*48575956LS mean19.519.820.220.9LS mean change (SE)3.5 (0.54)3.8 (0.49)4.2 (0.48)4.9 (0.50)Diff. vs placebo0.30.71.495 % CI−1.2, 1.7−0.7, 2.1−0.1, 2.9Baseline cACT Score ≥20*n*50394736LS mean22.921.521.922.5LS mean change (SE)0.8 (0.48)−0.5 (0.53)−0.2 (0.48)0.5 (0.55)Diff. vs placebo−1.3−1.0−0.495 % CI−2.8, 0.1−2.4, 0.4−1.8, 1.1*cACT* childhood asthma control test, *CI* confidence interval, *FEV* ~*1*~ forced expiratory volume in one second, *ITT* intention-to-treat, *LS* least squares, *PEF* peak expiratory flow, *SE* standard error, *VI* vilanterol^a^cACT data are post-hoc analyses

Secondary endpoints {#Sec10}
-------------------

Since the primary endpoint did not reach statistical significance, no inference was made for the secondary endpoints. A total of 384 (84 %) children completed a technically acceptable pre-bronchodilator FEV~1~ assessment at baseline. Of these, a total of 323 (71 %) children and 291 (64 %) children also completed an acceptable FEV~1~ assessment at Week 2 and Week 4, respectively. The analysis of change from baseline in trough FEV~1~ at Week 4 (LOCF) included 340 (75 %) children in the ITT population who provided technically acceptable FEV~1~ data both at baseline and at post-baseline. There was little difference in the change from baseline in trough FEV~1~ at Week 4 for each of the VI treatments compared with placebo (Table [3](#Tab3){ref-type="table"}).

Over the treatment period, the greatest treatment difference in change from baseline in the percentage of rescue-free 24-h periods was observed in the VI 25 treatment group when compared with placebo (Table [3](#Tab3){ref-type="table"}). This equated to an additional 0.6 rescue-free 24-h periods per week for children. For symptom-free days, the treatment differences observed between placebo and the VI 12.5 and VI 25 treatment groups, respectively, equate to an additional 0.6 and 0.7 symptom-free days per week. No difference in rescue-free or symptom-free days was found for the VI 6.25 group.

Across all secondary PEF endpoints, small but non-significant increases were seen with VI treatments compared with placebo. However, as with the primary endpoint, no dose--response was observed (Table [3](#Tab3){ref-type="table"}).

Children whose asthma was controlled at baseline (cACT score ≥20) experienced only small improvements in cACT score following treatment with VI compared with placebo, whereas in children with a cACT score \<20 at baseline, larger increases were observed (Table [3](#Tab3){ref-type="table"}).

Pharmacokinetics {#Sec11}
----------------

In total, 341 children (PK population) provided 780 PK samples. There was a very high proportion of pre-dose samples with non-quantifiable levels of VI, especially in the two lower dose groups (91, 94 and 74 % for the VI 6.25, VI 12.5 and VI 25 populations, respectively). At 10−15 min post-dose, the proportion of samples below the LLQ was 48, 30 and 20 % for the VI 6.25, VI 12.5 and VI 25 groups, respectively. The concentration-time data for the current study were combined with data from previous studies conducted in children with asthma receiving either VI 25 μg alone \[[@CR18]\] or in combination with FF \[[@CR17]\]. The mean plasma concentrations of VI 10−15 min post-dose were dose ordered and as expected for the doses administered (17.27 pg/mL, 40.04 pg/mL and 90.47 pg/mL, after treatment with VI 6.25 μg, VI 12.5 μg and VI 25 μg, respectively).

Safety {#Sec12}
------

The incidence of AEs during treatment was higher in the VI groups (28--33 %) than in the placebo group (22 %), but there was no apparent dose-ordering (Table [4](#Tab4){ref-type="table"}). The incidence of AEs considered to be drug-related by the investigator was 3 and 2 % in the VI 6.25 and VI 12.5 groups, respectively, with none reported in the placebo or VI 25 groups. The most frequently reported AE during the treatment period was nasopharyngitis. One child in each of the VI 6.25 and VI 25 groups experienced an AE leading to study withdrawal. The child in the VI 25 treatment group experienced an on-treatment non-fatal serious AE (SAE) of appendicitis and the child in the VI 6.25 treatment group experienced a viral respiratory tract infection. Neither AE was judged to be related to study treatment.Table 4Most frequent on-treatment AEs by preferred term (ITT population)AE (preferred term), *n* (%)PlaceboVI 6.25 μgVI 12.5 μgVI 25 μg*N* = 115*N* = 114*N* = 113*N* = 114Children with any AE25 (22)33 (29)37 (33)32 (28)Children with most frequent events15 (13)27 (24)26 (23)18 (16)Nasopharyngitis8 (7)8 (7)10 (9)9 (8)Headache4 (3)6 (5)2 (2)2 (2)Rhinitis3 (3)2 (2)3 (3)1 (\<1)Respiratory tract infection viral1 (\<1)3 (3)2 (2)1 (\<1)Rhinitis allergic02 (2)3 (3)2 (2)Abdominal pain1 (\<1)03 (3)2 (2)Bronchitis2 (2)3 (3)1 (\<1)0Pharyngitis1 (\<1)3 (3)02 (2)Influenza04 (4)00Ear pain003 (3)0All treatments were administered on a constant background of open-label FP 100 μg twice daily. Table shows events that occurred in ≥3 % in any treatment group*AE* adverse event, *ITT* intention-to-treat, *VI* vilanterol

Nine (2 %) children experienced asthma exacerbations during the treatment period (one child in the placebo group, three in the VI 6.25 group, one in the VI 12.5 group and four in the VI 25 group). None of these children were hospitalised but eight were withdrawn from the study as a result.

The mean changes from baseline in vital signs at Week 4 were small and similar between the placebo and VI treatment groups (least squares mean change in systolic BP: 0.1--1.1 mm Hg; diastolic BP: -0.1--0.4 mm Hg; pulse rate: -0.7--0.4 beats/min). Similarly, vital sign measurements at Week 2 and the maximum post-baseline changes showed only minor fluctuations from baseline. Abnormal ECG findings during the study were considered to be of potential clinical importance for 12 (3 %) children: two (2 %) children in the placebo group, six (5 %) children in the VI 6.25 μg group and two (2 %) children in each of the VI 12.5 and VI 25 groups. No AEs relating to ECG findings were reported during the study, and no children were withdrawn due to meeting the protocol-defined ECG stopping criteria.

Discussion {#Sec13}
==========

In this study, we observed that once-daily inhaled VI added to a low dose of ICS in children with inadequately controlled asthma showed no statistically significant benefit in PEF measurements over placebo, which we believe also indicates a lack of clinical benefit for this outcome measure. The small numeric improvements over placebo in evening PEF following VI treatment were not statistically significant for the highest dose of 25 μg, and therefore no inferences were made for the lower doses investigated in this study. No apparent dose--response was observed. Therefore, the study was unable to demonstrate an incremental benefit in selected lung function measures with the addition of VI to open-label FP in this paediatric population.

We selected trough (evening) PEF as the primary endpoint because it was considered a more accessible measure of lung function than FEV~1~, as good quality spirometry may be difficult to perform in children \[[@CR19]\]. However, PEF measurements have been reported to be variable \[[@CR20], [@CR21]\] and more so than FEV~1~ measurements \[[@CR22]\]. Thus, PEF measurements may have introduced a level of under or over estimation of the treatment benefit. A previous study of the ICS/LABA combination FP/salmeterol in children ages 4−11 years, showed an increase in evening PEF compared with FP alone (mean change \[standard error\] from baseline over Weeks 1−12: 21.5 L/min \[2.43\] and 15.1 L/min \[2.83\], respectively) \[[@CR23]\]. Furthermore, results of a Cochrane review comparing trials of 6--24 weeks duration in children found that a combination of LABA and ICS resulted in a significantly greater improvement in PEF compared with ICS monotherapy (morning PEF difference was 7.55 L/min and evening PEF was 5.5 L/min) \[[@CR6]\]. The treatment differences reported in these analyses are in line with our results, although statistical significance was not achieved in this study.

The children in the current study had inadequately controlled asthma and a mean percentage of pre- to post-bronchodilator PEF of 76.93 %. Therefore, a benefit would be expected in these children from the addition of LABA to their existing ICS therapy. Baseline cACT scores suggested a high proportion of controlled children (40−50 % cACT score ≥20), which could provide a possible explanation for the lack of efficacy observed in this study. Another possible reason that no significant benefit in PEF was observed is that ICS provide good control of asthma in children, \[[@CR24]\] thus reducing the potential for additional improvements in lung function. Of note, it is possible that children were more adherent to twice-daily ICS when in the trial compared with an unsupervised setting, as has been previously reported \[[@CR25]\].

The mean pre- and post-bronchodilator FEV~1~ at screening was 84.7 and 104.2 %, respectively, suggesting that children recruited into this study had the potential for improvement in FEV~1~ measurements by use of a bronchodilator. Large increases from baseline in trough FEV~1~ at Week 4 (LOCF) were observed for both VI and placebo treatment groups, hence the small treatment differences versus placebo. Considering the small increases observed in morning and evening PEF, these increases in FEV~1~ may have been due to improved ability to perform spirometric measures over time, by both children and investigators, in addition to the benefits with ICS and improved adherence discussed above.

In the secondary efficacy endpoint analyses, an increase for rescue-free 24-h periods was observed in the VI 25 group compared with placebo. Additionally, notable increases in symptom-free 24-h periods were observed for both VI 12.5 and VI 25 groups. The increase in rescue-free 24-h periods observed in the VI 25 group and those in symptom-free 24-h periods in the VI 12.5 and VI 25 groups exceed the lower bounds of the published minimal important differences in adults \[[@CR26]\]. This finding indirectly supports the importance of including more than just lung function measurements in the main analyses of studies in children. Indeed, a large long-term study in children with asthma aged 5--12 years found that ICS treatment had no effect on lung function but resulted in improvements in airway responsiveness and health outcomes over the 4--6-year treatment period \[[@CR27]\].

At the two lower doses of VI, the majority of PK samples were below quantifiable levels. The mean plasma concentration of VI 10−15 min post-dose was dose-ordered and systemic exposure observed for VI 25 μg was similar to that observed in a Phase IIa study of FF/VI 100/25 μg in children \[[@CR18]\]. As only one post-dose blood sample was collected, conclusions on maximum plasma concentration (C~max~) and time to maximum plasma concentration (t~max~) cannot be drawn from this study. However, studies in adults suggest that VI 25 μg is rapidly absorbed and eliminated from the systemic circulation \[[@CR28], [@CR29]\] and in children VI 25 μg has been shown to reach a C~max~ shortly after dosing (t~max~ of 12 min) \[[@CR18]\].

The incidence of overall AEs was similar across the VI treatment groups and slightly higher than in the placebo group, although there was no dose--response. The most common on-treatment AEs were those commonly observed in paediatric populations with asthma. The single SAE reported was not considered to be related to study treatment and there were no asthma-related hospitalisations or fatalities reported. The low number of exacerbations in each treatment group prevents meaningful comparisons between treatments.

Potential limitations of this study were the difficulty in recruiting children with poorly-controlled asthma on a background of ICS, and the variability of PEF measurements which may have further masked any treatment differences. The difficulty in obtaining FEV~1~ in young children means that using this as a primary endpoint requires an intensive programme to support coaching good quality spirometry from all children at all visits. The high number of study assessments was also a barrier to recruitment, and we recommend that study assessments are kept to a minimum for studies in children with asthma. Moreover, additional inclusion criteria based on cACT score at baseline, reflecting inadequately controlled asthma, could be used to ensure recruitment of a more clinically relevant population.

Conclusion {#Sec14}
==========

In summary, we found that the three doses of VI investigated in this study (6.25, 12.5 and 25 μg) did not significantly improve the change from baseline in daily pre-dose trough evening PEF in children ages 5−11 years and no dose--response was observed in change from baseline in evening PEF. Notable improvements over placebo were seen for VI 25 treatment in the percentage of rescue-free and symptom-free 24-h periods. All treatments were well tolerated and no new safety concerns were identified during the study.

AE

:   adverse event

ANCOVA

:   analysis of covariance

BP

:   blood pressure

cACT

:   childhood asthma control test

CI

:   confidence interval

C~max~

:   maximum plasma concentration

ECG

:   electrocardiogram

FEV~1~

:   forced expiratory volume in one second

FF

:   fluticasone furoate

FP

:   fluticasone propionate

ICS

:   inhaled corticosteroids

ITT

:   intention-to-treat

LABA

:   long-acting beta-2 agonist

LLQ

:   lower limit of quantification

LOCF

:   last observation carried forward

LS

:   least squares

MMRM

:   mixed modelling repeated measures

PEF

:   peak expiratory flow

PK

:   pharmacokinetic

PP

:   per protocol

SABA

:   short-acting inhaled beta-agonist

SAE

:   serious adverse event

SD

:   standard deviation

SE

:   standard error

t~max~

:   time to maximum plasma concentration

VI

:   vilanterol
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